SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2026 / Volume: 30 Issue: 2

Lamotrigine induced seizures in juvenile myoclonic epilepsy

Betül Acar
Ersel Dağ
Yakup Türkel
Pages
—
Publication Date
2013-07-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome.
📊
Key Findings & Data:Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy.
💡
Conclusion & Impact:We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antiepileptic drug · Seizure · Juvenile myoclonic epilepsy

Abstract

Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.

🔖

Cite This Article

Acar, B., Dağ, E., Türkel, Y. (2013). Lamotrigine induced seizures in juvenile myoclonic epilepsy. Journal of Experimental and Clinical Medicine, Volume: 30 Issue: 2. https://doi.org/10.5835/jecm.omu.30.02.027

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Atakli, D., Sözüer, D., Atay, T., Baybas, S., Arpaci, B., 1998. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 7, 63-66. Auvin, S., 2008. Treatment of juvenile myoclonic epilepsy. CNS Neurosci. Ther. 14, 227-233.
  2. Bodenstein-Sachar, H., Gandelman-Marton, R., Ben-Zeev, B., Chapman, J., Blatt, I., 2011. Outcome of LTG treatment in juvenile myoclonic epilepsy. Acta Neurol. Scand. 124, 22-27.
  3. Crespel, A., Genton, P., Berramdane, M., Coubes, P., Monicard, C., Baldy-Moulinier M., Gelisse, P., 2005. LTG associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology. 65, 762-764.
  4. Duncan, S., 2007. Teratogenesis of sodium VPA. Curr. Opin. Neurol. 20, 175-180.
  5. Janszky, J., Rásonyi, G., Halász, P., Olajos, S., Perenyi, J., 2000. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin. Neuropharmacol. 23, 86-89.
  6. Mantoan, L., Walker, M., 2011. Treatment options in juvenile myoclonic epilepsy. Curr. Treat. Options Neurol. 13, 355-370.
  7. Mehndiratta, M.M., Aggarwal, P., 2002. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India. Seizure. 11, 431-436.